RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen (NASDAQ:BIIB) and maintained a price target of $317.
June 26, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen and maintained a price target of $317.
The reiteration of an Outperform rating and a maintained price target of $317 by RBC Capital is a positive signal for Biogen's stock. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100